Kura Oncology, Inc. financial data

Symbol
KURA on Nasdaq
Industry
Pharmaceutical Preparations
Location
12730 High Bluff Drive, Suite 400, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
ZETA ACQUISITION CORP III (to 3/10/2015)
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.5K % -22.6%
Debt-to-equity 10.8 % +39.9%
Return On Equity -40.4 % -22.5%
Return On Assets -36.5 % -19.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 76.6M shares +3.23%
Common Stock, Shares, Outstanding 76.4M shares +3.07%
Entity Public Float 777M USD -35.3%
Common Stock, Value, Issued 8K USD +14.3%
Weighted Average Number of Shares Outstanding, Basic 86.6M shares +24.1%
Weighted Average Number of Shares Outstanding, Diluted 86.6M shares +24.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 138M USD +36.5%
General and Administrative Expense 62.2M USD +31.6%
Nonoperating Income (Expense) 18.3M USD +117%
Net Income (Loss) Attributable to Parent -182M USD -30%
Earnings Per Share, Basic -2.23 USD/shares -8.78%
Earnings Per Share, Diluted -2.23 USD/shares -8.78%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 45.2M USD -8.02%
Assets, Current 500M USD +2.91%
Property, Plant and Equipment, Net 1.52M USD -32.4%
Operating Lease, Right-of-Use Asset 6.4M USD +118%
Other Assets, Noncurrent 7.43M USD +101%
Assets 515M USD +4.12%
Accounts Payable, Current 2.06M USD -11.7%
Employee-related Liabilities, Current 8.93M USD +30.5%
Liabilities, Current 33.5M USD +40%
Operating Lease, Liability, Noncurrent 5.84M USD +302%
Other Liabilities, Noncurrent 1.18M USD +155%
Liabilities 49M USD +39.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax -463K USD +91.1%
Retained Earnings (Accumulated Deficit) -822M USD -28.4%
Stockholders' Equity Attributable to Parent 466M USD +1.39%
Liabilities and Equity 515M USD +4.12%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -48.8M USD -36.2%
Net Cash Provided by (Used in) Financing Activities 303K USD +284%
Net Cash Provided by (Used in) Investing Activities -95.3M USD -957%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 76.4M shares +3.07%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 4.19M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 45.2M USD -8.02%
Deferred Tax Assets, Valuation Allowance 224M USD +27.1%
Deferred Tax Assets, Gross 226M USD +27.4%
Operating Lease, Liability 7.31M USD +92.4%
Depreciation 234K USD +13.6%
Payments to Acquire Property, Plant, and Equipment 84K USD +133%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -177M USD -28.9%
Lessee, Operating Lease, Liability, to be Paid 10.4M USD +161%
Property, Plant and Equipment, Gross 4.39M USD +2.57%
Operating Lease, Liability, Current 1.47M USD -37.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.34M USD +44.7%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.96M USD +5.42%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure +109%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3.12M USD +1558%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.37M USD
Deferred Tax Assets, Operating Loss Carryforwards 144M USD +14.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 10.1M USD +56%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.4M USD
Operating Lease, Payments 500K USD -16.7%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 1.34M USD -28.6%
Interest Expense 1.6M USD +4.91%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%